Hikma Pharmaceuticals Plc Total Voting Rights (6293L)
01 Maggio 2020 - 12:30PM
UK Regulatory
TIDMHIK
RNS Number : 6293L
Hikma Pharmaceuticals Plc
01 May 2020
Hikma Pharmaceuticals PLC
Total Voting Rights and Capital
LONDON, 1 May 2020 - In accordance with the UK Financial Conduct
Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI:
549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the
market that as at 30 April 2020, its share capital consists of
242,543,355 ordinary shares with voting rights. There are nil
shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FCA's DTR's.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREASSFESDEEEA
(END) Dow Jones Newswires
May 01, 2020 06:30 ET (10:30 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2023 a Mar 2024